Potential Risks and Benefits of Gain-of-Function Research: Summary of a Workshop (2015)
Chapter: Appendix F: Acronym List
ABSL | animal biosafety level |
ACE-2 receptor | Angiotensin-converting enzyme 2 |
APHIS | Animal and Plant Health Inspection Service |
BARDA | Biomedical Advanced Research and Development Authority |
BMBL | Biosafety in Microbiological and Biomedical Laboratories |
BSAT | Biological Select Agents and Toxins |
BSL | biosafety level |
CDC | U.S. Centers for Disease Control and Prevention |
cDNA | complementary deoxyribonucleic acid |
CoV | coronavirus |
CRISPR | clustered regularly interspaced short palindromic repeats |
DNA | deoxyribonucleic acid |
DURC | dual use research of concern |
EID | Emerging Infectious Diseases |
FBI | Federal Bureau of Investigation |
GAO | Government Accountability Office |
GOF | gain-of-function |
HA | hemagglutinins |
HAE | human airway epithelial |
HEPA | high-efficiency particulate arrestance |
HPAIV | highly pathogenic avian influenza viruses |
IACUC | Institutional Animal Care and Use Committees |
IBC | Institutional Biosafety Committee |
IOM | Institute of Medicine |
IRI | Influenza Research Institute (at the University of Wisconsin-Madison) |
JCVI | J. Craig Venter Institute |
LAI | Laboratory Acquired Infection |
mAb | monoclonal antibody |
MERS | Middle East respiratory syndrome |
NA | neuraminidase |
NAS | National Academy of Sciences |
NIAID | National Institute of Allergy and Infectious Diseases |
NIH | National Institutes of Health |
NSABB | National Science Advisory Board for Biosecurity |
NRC | National Research Council |
PLoS | Public Library of Science |
PPE | personal protective equipment |
PPP | potential pandemic pathogens |
RNA | ribonucleic acid |
SARS | severe acute respiratory syndrome |
SGVI | Synthetic Genomics Vaccines |
SL-CoV | SARS-like CoV |
S&T | science and technology |
UPMC | University of Pittsburgh Medical Center |
USDA | U.S. Department of Agriculture |
USG | U.S. Government |
USNRC | U.S. Nuclear Regulatory Commission |
